Tag: AML
-
Goddess of Wealth Conwoman Jailed Over £5bn Bitcoin Hoard
London’s High-Stakes Bitcoin Case Finally Concludes The so-called “Goddess of Wealth” was sentenced to 11 years and eight months in prison after being found guilty in the UK’s most valuable money laundering investigation to date. Zhimin Qian, 47, had spent nearly five years on the run before her capture, and authorities said her alleged hoard…
-
Two Suspects in S$3 Billion Money Laundering Case Spent S$69.8 Million on London Properties While Evading Singapore Authorities
Overview Two suspects tied to a S$3 billion money laundering case reportedly spent about S$69.8 million on properties in London while evading Singapore authorities in 2023. The revelation adds a new layer to the high-profile case, highlighting how proceeds from criminal activity can be laundered through real estate markets abroad. Local investigators have been coordinating…
-
Luxury Watches and Jewellery: The Extravagant Life of an Alleged NAB Fraudster
Inside Australia’s Luxury Market and a High-Stakes Case The case surrounding an alleged National Australia Bank (NAB) fraudster has illuminated a world where luxury watches, jewellery, and other high-value assets intersect with money laundering and complex financial crime. While authorities pursue charges and details remain disputed, the investigation has sparked wider questions about how wealth…
-
Heart Failure in AML: New Evidence on Anthracycline Cardiotoxicity
Overview A comprehensive meta-analysis led by researchers from the Netherlands sheds new light on the risk of heart failure in patients with acute myeloid leukemia (AML) who receive anthracycline-based induction therapy. By systematically reviewing 41 studies including 5,995 AML patients, the study consolidates what clinicians have long suspected: anthracyclines, while effective for achieving remission, carry…
-
Heart Failure in AML: New Evidence Emerges
New Evidence on Cardiotoxicity in AML Treatment A comprehensive new systematic review analyzed 41 studies involving 5,995 patients with acute myeloid leukemia (AML) who received anthracycline-based regimens during remission induction. The pooled rate of heart failure in this population was 3.2%, with notable differences depending on the anthracycline used: 2.3% with daunorubicin, 5.0% with idarubicin,…
-
New Evidence on Heart Failure in AML Treated with Anthracyclines: What Clinicians Need to Know
Overview Heart failure in AML remains a critical concern for patients undergoing induction therapy with anthracycline-based regimens. A comprehensive meta-analysis led by researchers in the Netherlands analyzed 41 studies totaling 5,995 AML patients. The study quantified the burden of heart failure and highlighted substantial variability depending on the specific anthracycline used. These findings reinforce the…